FOXO4-DRI Peptide – Kodiac biolabs

Our opinion on this compoundNovel, promising

59/100

Elegant senolytic probe targeting the FOXO4-p53 axis, but single-lab preclinical with no human data

Look, the de Keizer 2017 Cell paper genuinely changed how the field thought about senescent cell survival. The core insight is elegant: senescent cells dont die the way they should because FOXO4 physically sequesters nuclear p53, keeping it away from its apoptotic signaling role. FOXO4-DRI is a retroinverso peptide, all D-amino acids with a reversed sequence, that competitively disrupts that interaction. Release p53, and senescent cells kill themselves. Healthy cells, which dont rely on the FOXO4-p53 interaction for survival, are largely spared. That selectivity profile is what separates this from blunter instruments like navitoclax or ABT-263, which hit BCL-2 family members broadly and carry meaningful toxicity.

The retroinverso design is worth understanding. D-amino acids make the peptide protease-resistant in a way that L-amino acid counterparts simply arent; the reversed sequence preserves the structural mimicry of the FOXO4 target region while delivering a pharmacokinetically more tractable molecule. A penetratin sequence handles cell entry. As research tools go, this is carefully engineered, not a peptide fragment someone threw at a model.

What we like here is the mechanism specificity. Most senolytics in the current literature are repurposed oncology drugs (navitoclax) or phenolic compounds with broad polypharmacology (dasatinib plus quercetin). A peptide operating directly at a protein-protein interface defined by senescent cell biology is a much cleaner probe. If you want to ask what happens when you remove senescent cells without the noise of BCL-2 inhibition or kinase off-targets, FOXO4-DRI is one of the few tools that lets you do it.

The problems are real, though. The Hubrecht group dominates the primary literature; external replication of the full rejuvenation story is limited, and the 2017 mouse data showing improved fur density, kidney function recovery, and enhanced physical performance has been cited extensively but not reproduced cleanly outside the originating lab at the same scale. There are no human clinical trials. Synthesis of D-retroinverso peptides at research grade is possible but not commoditized, so sourcing adds friction.

Honestly, the bench value is what keeps this genuinely interesting. For investigators studying the SASP, comparing senolytic modalities in aging tissue models, or probing p53 biology in the context of cellular senescence, this is a nearly irreplaceable tool. Theres nothing else that hits the FOXO4-p53 axis the same way. The score reflects that the preclinical case is real and the probe is unique, but the evidence base is thin and the translational distance is long.

Novelty: 65
Mechanism promise: 78
In-category differentiation: 68
Evidence quality: 38
Translational signal: 25
Research bench value: 72

Rationale The de Keizer Cell 2017 mechanism is genuinely novel and the selectivity profile distinguishes this from blunter senolytics, pushing mechanism and differentiation scores meaningfully above field average. Evidence and translational scores are sharply constrained by Hubrecht-group concentration in the primary literature and a complete absence of human trials, landing the overall at 59.

Cell-penetrating peptide senolytic

A retroinverso D-amino acid peptide that disrupts the FOXO4-p53 interaction in senescent cells, selectively triggering apoptosis.

Abstract

FOXO4-DRI (FOXO4-D-retroinverso peptide; sequence ltlrkepaseiaqsileayqqgs in D-amino acids; molecular weight approximately 2700 Da) is a designed cell-penetrating peptide senolytic developed by de Keizer and colleagues at the Hubrecht Institute. The compound is a retroinverso peptide derived from the FOXO4 sequence that competitively disrupts the FOXO4-p53 interaction; in senescent cells, FOXO4 sequesters nuclear p53 and prevents apoptosis. The DRI peptide releases p53, which translocates to mitochondria and triggers selective apoptosis in senescent cells while sparing healthy cells (which do not depend on the FOXO4-p53 interaction for survival). Mouse studies (Cell 2017) demonstrated dramatic rejuvenation of fur density, kidney function, and physical performance in aged mice. The retroinverso D-amino acid construction confers protease resistance; cell penetration is supported by an attached penetratin sequence. No human clinical trials at this writing. The compound is a research tool for academic senolytic biology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-300Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.